Search research articles
Contact Us
Filters
Showing results (371-380 of 391) with videos related to
Page
of 40
Sort By:
JAMA Surgery
|
July 2, 2025
Rizedisben in Minimally Invasive Surgery: A Nonrandomized Clinical Trial
Samuel A Gold, Maria M Pere, Melissa Assel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2025
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial
Jonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
The New England Journal of Medicine
|
March 3, 2021
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Toni K Choueiri, Thomas Powles, Mauricio Burotto, et al.
European Urology
|
April 9, 2026
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [<sup>177</sup>Lu] Lu-PSMA-617 (ANZUP1901)
Louise Emmett, Nathan Papa, Oliver Sartor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2023
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
Emmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh, et al.
The Lancet. Oncology
|
April 20, 2020
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, et al.
Clinical Genitourinary Cancer
|
June 8, 2022
Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy
Min Yuen Teo, Brendan J Guercio, Arshi Arora, et al.
JCO Precision Oncology
|
June 22, 2022
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype
Nima Almassi, Karissa Whiting, Antoun Toubaji, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 11, 2025
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial
Ana Oaknin, Bradley J Monk, Andreia Cristina de Melo, et al.
European Urology
|
April 27, 2025
Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma
Carissa E Chu, Ziyu Chen, Karissa Whiting, et al.
Page
of 40
Search research articles
Search
Showing results (371-380 of 391) with videos related to
Sort By:
Page
of 40
JAMA Surgery
|
July 2, 2025
Rizedisben in Minimally Invasive Surgery: A Nonrandomized Clinical Trial
Samuel A Gold, Maria M Pere, Melissa Assel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2025
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial
Jonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
The New England Journal of Medicine
|
March 3, 2021
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Toni K Choueiri, Thomas Powles, Mauricio Burotto, et al.
European Urology
|
April 9, 2026
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [<sup>177</sup>Lu] Lu-PSMA-617 (ANZUP1901)
Louise Emmett, Nathan Papa, Oliver Sartor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2023
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
Emmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh, et al.
The Lancet. Oncology
|
April 20, 2020
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, et al.
Clinical Genitourinary Cancer
|
June 8, 2022
Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy
Min Yuen Teo, Brendan J Guercio, Arshi Arora, et al.
JCO Precision Oncology
|
June 22, 2022
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype
Nima Almassi, Karissa Whiting, Antoun Toubaji, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 11, 2025
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial
Ana Oaknin, Bradley J Monk, Andreia Cristina de Melo, et al.
European Urology
|
April 27, 2025
Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma
Carissa E Chu, Ziyu Chen, Karissa Whiting, et al.
Page
of 40